Annual Total Liabilities
$26.64 M
+$6.79 M+34.24%
December 31, 2023
Summary
- As of February 8, 2025, SABS annual total liabilities is $26.64 million, with the most recent change of +$6.79 million (+34.24%) on December 31, 2023.
- During the last 3 years, SABS annual total liabilities has risen by +$9.11 million (+51.98%).
- SABS annual total liabilities is now -37.45% below its all-time high of $42.59 million, reached on December 31, 2021.
Performance
SABS Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$16.89 M
+$1.12 M+7.12%
September 30, 2024
Summary
- As of February 8, 2025, SABS quarterly total liabilities is $16.89 million, with the most recent change of +$1.12 million (+7.12%) on September 30, 2024.
- Over the past year, SABS quarterly total liabilities has increased by +$3.81 million (+29.16%).
- SABS quarterly total liabilities is now -60.33% below its all-time high of $42.59 million, reached on December 31, 2021.
Performance
SABS Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
SABS Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +34.2% | +29.2% |
| 3 y3 years | +52.0% | -22.8% |
| 5 y5 years | +31.2% | -22.8% |
SABS Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -37.5% | +34.2% | -60.3% | +29.2% |
| 5 y | 5-year | -37.5% | +52.0% | -60.3% | +67.7% |
| alltime | all time | -37.5% | +52.0% | -60.3% | +67.7% |
SAB Biotherapeutics Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $16.89 M(+7.1%) |
| Jun 2024 | - | $15.77 M(-15.0%) |
| Mar 2024 | - | $18.55 M(-30.4%) |
| Dec 2023 | $26.64 M(+34.2%) | $26.64 M(+103.7%) |
| Sep 2023 | - | $13.08 M(-16.8%) |
| Jun 2023 | - | $15.73 M(-13.9%) |
| Mar 2023 | - | $18.27 M(-7.9%) |
| Dec 2022 | $19.85 M | $19.85 M(-9.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2022 | - | $21.88 M(-0.7%) |
| Jun 2022 | - | $22.03 M(-15.9%) |
| Mar 2022 | - | $26.21 M(-38.5%) |
| Dec 2021 | $42.59 M(+143.0%) | $42.59 M(+322.9%) |
| Sep 2021 | - | $10.07 M(-36.9%) |
| Jun 2021 | - | $15.95 M(-9.0%) |
| Dec 2020 | $17.53 M(-13.7%) | $17.53 M |
| Dec 2019 | $20.31 M | - |
FAQ
- What is SAB Biotherapeutics annual total liabilities?
- What is the all time high annual total liabilities for SAB Biotherapeutics?
- What is SAB Biotherapeutics annual total liabilities year-on-year change?
- What is SAB Biotherapeutics quarterly total liabilities?
- What is the all time high quarterly total liabilities for SAB Biotherapeutics?
- What is SAB Biotherapeutics quarterly total liabilities year-on-year change?
What is SAB Biotherapeutics annual total liabilities?
The current annual total liabilities of SABS is $26.64 M
What is the all time high annual total liabilities for SAB Biotherapeutics?
SAB Biotherapeutics all-time high annual total liabilities is $42.59 M
What is SAB Biotherapeutics annual total liabilities year-on-year change?
Over the past year, SABS annual total liabilities has changed by +$6.79 M (+34.24%)
What is SAB Biotherapeutics quarterly total liabilities?
The current quarterly total liabilities of SABS is $16.89 M
What is the all time high quarterly total liabilities for SAB Biotherapeutics?
SAB Biotherapeutics all-time high quarterly total liabilities is $42.59 M
What is SAB Biotherapeutics quarterly total liabilities year-on-year change?
Over the past year, SABS quarterly total liabilities has changed by +$3.81 M (+29.16%)